|
ATE303399T1
(de)
|
2001-03-12 |
2005-09-15 |
Intercept Pharmaceuticals Inc |
Steroide als agonisten für fxr
|
|
DK2712617T3
(en)
|
2004-03-12 |
2017-02-13 |
Intercept Pharmaceuticals Inc |
Treatment of fibrosis with Fxr ligands.
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
ES2523591T3
(es)
|
2006-06-27 |
2014-11-27 |
Intercept Pharmaceuticals Inc. |
Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
|
|
WO2008091540A2
(en)
|
2007-01-19 |
2008-07-31 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as tgr5 modulators and methods of use thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2010014836A2
(en)
*
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
DK2376519T3
(da)
|
2008-11-19 |
2014-02-03 |
Intercept Pharmaceuticals Inc |
TGR5-modulatorer og fremgangsmåde til anvendelse deraf
|
|
US9339480B2
(en)
|
2008-11-26 |
2016-05-17 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
US8318663B2
(en)
|
2008-11-26 |
2012-11-27 |
Satiogen Pharmaceuticals, Inc. |
Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
|
|
EP2379081B1
(en)
|
2008-12-19 |
2013-03-20 |
Royal College of Surgeons in Ireland |
Treatment of diarrhoea
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
ITRM20100329A1
(it)
*
|
2010-06-15 |
2011-12-16 |
Franco Baldelli |
Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
EP2525223A1
(en)
*
|
2011-05-19 |
2012-11-21 |
Universiteit Maastricht |
In vitro method for predicting in vivo genotoxicity of chemical compounds.
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US11154559B2
(en)
|
2011-09-29 |
2021-10-26 |
Ethicon Endo-Surgery, Inc. |
Methods and compositions of bile acids
|
|
EA201891154A1
(ru)
|
2011-10-28 |
2019-02-28 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
|
|
EA038594B1
(ru)
|
2011-10-28 |
2021-09-21 |
Шайр Хьюман Дженетик Терапис, Инк. |
Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
|
|
EA201990211A1
(ru)
|
2012-06-19 |
2019-06-28 |
Интерсепт Фармасьютикалз, Инк. |
Получение, применение и твердые формы обетихолевой кислоты
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
MX361653B
(es)
*
|
2012-10-26 |
2018-12-13 |
Intercept Pharmaceuticals Inc |
Procedimiento para la preparación de derivados del ácido biliar.
|
|
KR102106186B1
(ko)
*
|
2012-11-28 |
2020-05-04 |
인터셉트 파마슈티컬즈, 인크. |
폐 질환의 치료
|
|
ES2847002T3
(es)
*
|
2013-05-14 |
2021-07-30 |
Intercept Pharmaceuticals Inc |
Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
|
|
CA2914924A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceuticals B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
NZ716568A
(en)
*
|
2013-08-01 |
2021-07-30 |
Us Health |
Inhibitors of the farnesoid x receptor and uses in medicine
|
|
AU2014320463B2
(en)
|
2013-09-11 |
2018-08-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
|
|
MX356006B
(es)
*
|
2013-10-18 |
2018-04-24 |
Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C |
Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
|
|
EP3071696B1
(en)
|
2013-11-22 |
2019-08-07 |
Mina Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
ES2860423T3
(es)
|
2014-05-28 |
2021-10-05 |
Childrens Hospital Med Ct |
Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
|
|
RS64050B1
(sr)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S R L |
Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti
|
|
WO2016049069A1
(en)
|
2014-09-24 |
2016-03-31 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
|
CN106459136B
(zh)
*
|
2014-09-28 |
2018-06-26 |
江苏盛迪医药有限公司 |
一种奥贝胆酸的制备方法
|
|
WO2016061464A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
|
|
KR20170094184A
(ko)
*
|
2014-11-06 |
2017-08-17 |
이난타 파마슈티칼스, 인코포레이티드 |
Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
|
|
PL3221332T3
(pl)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
|
|
DK3221333T3
(da)
|
2014-11-19 |
2019-09-30 |
Nzp Uk Ltd |
6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
|
|
BR112017010319B1
(pt)
|
2014-11-19 |
2023-04-11 |
NZP UK Limited |
Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
|
|
WO2016079520A1
(en)
|
2014-11-19 |
2016-05-26 |
Dextra Laboratories Limited |
6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
|
|
KR20170099909A
(ko)
|
2014-11-26 |
2017-09-01 |
이난타 파마슈티칼스, 인코포레이티드 |
Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
|
|
WO2016086115A1
(en)
*
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EA036404B1
(ru)
|
2015-02-06 |
2020-11-06 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции для комбинированной терапии
|
|
SG11201706089RA
(en)
|
2015-02-11 |
2017-09-28 |
Enanta Pharm Inc |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
PT3277286T
(pt)
|
2015-03-31 |
2021-07-01 |
Enanta Pharm Inc |
Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
|
|
PE20180034A1
(es)
|
2015-04-07 |
2018-01-09 |
Intercept Pharmaceuticals Inc |
Composiciones farmaceuticas para terapias combinadas
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
WO2017053428A1
(en)
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
KR20180052756A
(ko)
*
|
2015-09-24 |
2018-05-18 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
|
EP3359160B1
(en)
*
|
2015-10-07 |
2021-08-25 |
Intercept Pharmaceuticals, Inc. |
Farnesoid x receptor modulators
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
WO2017142895A1
(en)
*
|
2016-02-15 |
2017-08-24 |
Regents Of The University Of Minnesota |
Compositions and methods for treating clostridium associated diseases
|
|
US20170233431A1
(en)
*
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
CN109152840A
(zh)
|
2016-03-28 |
2019-01-04 |
英特塞普特医药品公司 |
通过结合fxr激动剂和arb获得的药物
|
|
CA3020698A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
|
JP6963882B2
(ja)
|
2016-05-05 |
2021-11-10 |
チルドレンズ ホスピタル メディカル センター |
胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
JP6678779B2
(ja)
|
2016-06-13 |
2020-04-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒ（ｎｒ１ｈ４）調節化合物
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
CN109963567A
(zh)
*
|
2016-09-30 |
2019-07-02 |
英特塞普特医药品公司 |
胆汁酸衍生物的结晶形式
|
|
EP3534907A4
(en)
|
2016-11-04 |
2020-06-24 |
Children's Hospital Medical Center |
COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASE
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
WO2018102418A1
(en)
|
2016-11-29 |
2018-06-07 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonylurea bile acid derivatives
|
|
EP3548507A4
(en)
|
2016-12-05 |
2020-07-15 |
Children's Hospital Medical Center |
COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
US20180256600A1
(en)
*
|
2017-03-07 |
2018-09-13 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
TW201832768A
(zh)
*
|
2017-03-07 |
2018-09-16 |
英特賽普醫藥品公司 |
治療癌症的方法
|
|
PT4122464T
(pt)
|
2017-03-28 |
2024-06-27 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças do fígado
|
|
US20210085662A1
(en)
|
2017-03-30 |
2021-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
WO2018187804A1
(en)
|
2017-04-07 |
2018-10-11 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonyl carbamate bile acid derivatives
|
|
EP3609997A4
(en)
|
2017-04-14 |
2021-03-03 |
Children's Hospital Medical Center |
COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
|
|
CN111050772A
(zh)
|
2017-07-24 |
2020-04-21 |
英特塞普特医药品公司 |
同位素标记的胆汁酸衍生物
|
|
EP3679139B1
(en)
|
2017-09-08 |
2022-11-02 |
MiNA Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
CA3077442A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
WO2019126626A1
(en)
|
2017-12-21 |
2019-06-27 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
SG11202100533VA
(en)
|
2018-07-26 |
2021-02-25 |
Childrens Hospital Med Ct |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US11208571B2
(en)
|
2018-08-08 |
2021-12-28 |
University Of Maryland, College Park |
Methods for nondestructive dispersing of carbon nanomaterials in water
|
|
CA3112026A1
(en)
|
2018-09-12 |
2020-03-19 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
SG11202107434PA
(en)
|
2019-01-15 |
2021-08-30 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
EP3920937A4
(en)
*
|
2019-02-04 |
2022-11-02 |
Intercept Pharmaceuticals, Inc. |
TREATMENT AND PREVENTION OF INFLAMATORY BOWEL DISEASES WITH A BILE ACID DERIVATIVE
|
|
CN118388473A
(zh)
|
2019-02-19 |
2024-07-26 |
吉利德科学公司 |
Fxr激动剂的固体形式
|
|
WO2020243590A1
(en)
|
2019-05-30 |
2020-12-03 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
US12497597B2
(en)
|
2019-05-31 |
2025-12-16 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
CN112142814B
(zh)
*
|
2019-06-26 |
2021-09-28 |
江苏吉贝尔药业股份有限公司 |
牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
|
|
CA3139291A1
(en)
|
2019-07-18 |
2021-01-21 |
Jacky Vonderscher |
Method for decreasing adverse-effects of interferon
|
|
WO2021144330A1
(en)
|
2020-01-15 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
MX2023008365A
(es)
|
2021-01-14 |
2023-10-04 |
Enyo Pharma |
Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
|
|
US20240216364A1
(en)
|
2021-04-28 |
2024-07-04 |
Enyo Pharma |
Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
|
|
CN119950519B
(zh)
*
|
2025-01-07 |
2025-11-21 |
山东省海洋科学研究院(青岛国家海洋科学研究中心) |
奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用
|